Therapy of brain tumors by inhibition of nuclear receptor tailles (Tlx)
DKFZ researchers identified nuclear receptor tailles (Tlx) as a valuable drug target for brain tumors especially gliobastomas. In vivo experiments showed almost doubling in survival time of mice harbouring brain tumors by inhibiting the expression of Tlx in tumor cells. In addition a highly significant correlation between expression of Tlx in brain tumor cells and survival of the patient was demonstrated.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
New organoid with all key pancreas cells
Researchers from the Organoid group (previously Clevers group) at the Hubrecht Institute have developed a new organoid that mimics the human fetal pancreas, offering a clearer view of its early development….
Unlocking the potential of nickel
New study reveals how to use single atoms to turn CO2 into valuable chemical resources. Nickel and nitrogen co-doped carbon (Ni-N-C) catalysts have shown exceptional performance in converting CO2 into…
‘Spooky action’ at a very short distance
Scientists map out quantum entanglement in protons. Particles streaming from collisions offer insight into dynamic interactions and collective behavior of quarks and gluons. Scientists at the U.S. Department of Energy’s…